KR 339 in the treatment of Parkinsonian tremor.
D000368:Aged; D000547:Amantadine / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001799:Blood Sedimentation; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004048:Diethylamines / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy*; D010919:Placebos; D013997:Time Factors; D014202:Tremor / Q000188:drug therapy*
D000978:Antiparkinson Agents; D001952:Bridged-Ring Compounds; D004048:Diethylamines; D010276:Parasympatholytics; D010919:Placebos; D004295:Dihydroxyphenylalanine; C006088:bornaprine; D000547:Amantadine